MF Capital

MF Capital concentrates on China's consumer healthcare sector, with medical aesthetics as its core vertical. The firm invests in the supply chain that equips aesthetic clinics — including ophthalmic implants, injectable biomaterials, energy-based devices, and specialized clinical service platforms — rather than the clinics themselves. This manufacturer-and-supplier orientation distinguishes its portfolio construction from healthcare funds that balance device, drug, and service exposures (per firm website).

Founding partner 金雪坤 leads the firm. The investment team includes professionals with doctoral and postdoctoral training from institutions in China, the United States, and Hong Kong, with specific expertise in medical device regulatory pathways and clinical adoption in the Chinese market (per firm website). Day-to-day investment committee composition and any external advisory board are not publicly disclosed.

The firm invests directly out of its own RMB-denominated funds — five vehicles to date — rather than operating as a fund-of-funds. All disclosed portfolio holdings are direct equity positions in operating companies spanning early-stage through growth equity. There is no public record of MF Capital committing capital to third-party funds (per firm website).

MF Capital leverages its concentration in medical aesthetics — a narrow sub-vertical — and the professional networks of a team that bridges clinical, regulatory, and manufacturing expertise. The firm's Chengdu and Beijing dual-office structure connects it to both the southwestern China consumption market and the national medical-device regulatory apparatus in the capital, but the firm does not publicly detail specific sourcing channels beyond its sector specialization (per firm website).

No philanthropic foundation, donor-advised fund, or charitable vehicle affiliated with MF Capital or its principals is publicly disclosed. The firm appears organized purely as a for-profit private equity manager within China's regulatory framework for qualified私募管理人 (private fund managers) registered with the Asset Management Association of China (per firm website).

MF Capital does not publish an explicit exclusion list. However, its entire portfolio and public messaging reference only consumer healthcare and medical aesthetics. There is no evidence of investment in broader healthcare verticals such as innovative pharmaceuticals, traditional medical devices outside aesthetic applications, hospital chains beyond the single disclosed clinic investment, or non-healthcare sectors (per firm website).

The firm has not publicly disclosed a co-investment program, club-deal structure, or minority participation alongside other general partners. All disclosed investments appear to be direct and proprietary to MF Capital's own funds. Whether the firm accepts co-investment from limited partners on a deal-by-deal basis is not stated in available materials (per firm website).